Literature DB >> 22819091

Early spondyloarthritis.

Denis Poddubnyy1, Martin Rudwaleit.   

Abstract

Spondyloarthritis (SpA) is a large family of chronic inflammatory diseases characterized by inflammation of the axial skeleton, a typically asymmetric peripheral arthritis of the lower limbs, enthesitis, typical extra-articular manifestations, and shared genetic background. The prevalence in the general population is up to 2% for the entire group. SpA, particularly ankylosing spondylitis, has been associated with a diagnostic delay of up to 10 years. Important efforts toward shortening this delay have been made, including the development of new classification criteria. This article discusses the current concept of the disease, typical manifestations, advances in diagnosis, and current treatment recommendations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819091     DOI: 10.1016/j.rdc.2012.04.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  15 in total

Review 1.  Management of Uveitis in Spondyloarthropathy: Current Trends.

Authors:  Nikhil Gupta; Aditi Agarwal
Journal:  Perm J       Date:  2018

Review 2.  Axial spondyloarthritis classification criteria: the debate continues.

Authors:  Maureen Dubreuil; Atul A Deodhar
Journal:  Curr Opin Rheumatol       Date:  2017-07       Impact factor: 5.006

Review 3.  Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia.

Authors:  Hanan Al Rayes; Mansour Alazmi; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi; Suzan Attar
Journal:  Clin Rheumatol       Date:  2022-01-08       Impact factor: 2.980

4.  Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis.

Authors:  Trevor Persaud; Richard Morgan; Hein Linn Thant; Francis J DeAsis; Felix Ferre; Jose Diaz
Journal:  Am J Case Rep       Date:  2022-07-01

5.  Axial spondyloarthritis criteria and modified NY criteria: issues and controversies.

Authors:  Atul Deodhar
Journal:  Clin Rheumatol       Date:  2014-05-17       Impact factor: 2.980

6.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Authors:  R Landewé; J Braun; A Deodhar; M Dougados; W P Maksymowych; P J Mease; J D Reveille; M Rudwaleit; D van der Heijde; C Stach; B Hoepken; A Fichtner; G Coteur; M de Longueville; J Sieper
Journal:  Ann Rheum Dis       Date:  2013-09-06       Impact factor: 19.103

Review 7.  HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the strength of association with axial spondyloarthritis and methodological gaps.

Authors:  Nelly Raymond Ziade
Journal:  BMC Musculoskelet Disord       Date:  2017-06-29       Impact factor: 2.362

Review 8.  Application of machine learning in the diagnosis of axial spondyloarthritis.

Authors:  Jessica A Walsh; Martin Rozycki; Esther Yi; Yujin Park
Journal:  Curr Opin Rheumatol       Date:  2019-07       Impact factor: 5.006

9.  The IMPACT study: A clustered randomized controlled trial to assess the effect of a referral algorithm for axial spondyloarthritis.

Authors:  Maha Jamal; Amber M Korver; Martijn Kuijper; Deirisa Lopes Barreto; Cathelijne W Y Appels; Anneke P L Spoorenberg; Bart W Koes; Johanna M W Hazes; Lonneke van Hoeven; Angelique E A M Weel
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

10.  Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.

Authors:  Luca Cantarini; Marta Fabbroni; Rosaria Talarico; Luisa Costa; Francesco Caso; Gian Luca Cuneo; Bruno Frediani; Gabriele Faralli; Antonio Vitale; Maria Giuseppina Brizi; Luciano Sabadini; Mauro Galeazzi
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.